Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD) by Seini Moimoi | Jan 11, 2023 | Portfolio News
Orbus Therapeutics Enters Exclusive License Agreement for Intellectual Property Related to Treatment of Rare Pediatric Syndrome with Eflornithine by Seini Moimoi | Jan 10, 2023 | Portfolio News
Avenge Bio Announces Dosing of First Patient in Phase 1/2 Clinical Trial Evaluating AVB-001 for the Treatment of Ovarian Cancer by Seini Moimoi | Jan 9, 2023 | Portfolio News
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED) by Seini Moimoi | Jan 8, 2023 | Portfolio News
Nalu Medical, Inc., Announces Publication of Two Spinal Cord Stimulation Clinical Studies by Seini Moimoi | Jan 5, 2023 | Portfolio News
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults by Seini Moimoi | Jan 5, 2023 | Portfolio News
